{"entity":"abbvie","id":"ent_abbvie","name":"AbbVie","from":"2025-11-08","to":"2026-11-08","page":"https://asof.is/record/abbvie/diff?from=2025-11-08&to=2026-11-08","summary":"Between 2025-11-08 and 2026-11-08, AbbVie's record changed in 17 facts: 3 replaced (net income $4.28 billion → $4.23 billion; operating income $9.14 billion → $15.08 billion; revenue $56.33 billion → $61.16 billion), 7 added, 7 ended; 8 unchanged.","counts":{"changed":17,"added":7,"ended":7,"replaced":3,"unchanged":8,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_operating_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_A17F69D94691","predicate":"cash_and_equivalents","value":"10,774,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 10,774,000,000 United States dollar\", as of 2026-09-30. Claim clm_A17F69D94691, https://asof.is/claim/clm_A17F69D94691, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_A17F69D94691","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_B8246C4E0E64","predicate":"quarterly_net_income","value":"4,218,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 4,218,000,000 United States dollar\", as of 2026-09-30. Claim clm_B8246C4E0E64, https://asof.is/claim/clm_B8246C4E0E64, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_B8246C4E0E64","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_5AF8A08D6F94","predicate":"quarterly_operating_income","value":"6,267,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 6,267,000,000 United States dollar\", as of 2026-09-30. Claim clm_5AF8A08D6F94, https://asof.is/claim/clm_5AF8A08D6F94, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_5AF8A08D6F94","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_DA52AAE1BFB4","predicate":"quarterly_revenue","value":"17,404,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 17,404,000,000 United States dollar\", as of 2026-09-30. Claim clm_DA52AAE1BFB4, https://asof.is/claim/clm_DA52AAE1BFB4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_DA52AAE1BFB4","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_54135339A00E","predicate":"shares_outstanding","value":"1,767,616,306 shares","valid_from":"2026-10-26","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,616,306 shares\", as of 2026-10-26. Claim clm_54135339A00E, https://asof.is/claim/clm_54135339A00E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_54135339A00E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_0DE2793ECF77","predicate":"total_assets","value":"147,680,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 147,680,000,000 United States dollar\", as of 2026-09-30. Claim clm_0DE2793ECF77, https://asof.is/claim/clm_0DE2793ECF77, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_0DE2793ECF77","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_FA883B408C6E","predicate":"total_equity","value":"-4,583,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -4,583,000,000 United States dollar\", as of 2026-09-30. Claim clm_FA883B408C6E, https://asof.is/claim/clm_FA883B408C6E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_FA883B408C6E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}}],"ended":[{"id":"clm_E498EA77B417","predicate":"cash_and_equivalents","value":"5,629,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,629,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E498EA77B417, https://asof.is/claim/clm_E498EA77B417, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E498EA77B417","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F526599F9FFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_48C26099DBC0","predicate":"quarterly_net_income","value":"186,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 186,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_48C26099DBC0, https://asof.is/claim/clm_48C26099DBC0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_48C26099DBC0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_879DEDC1ACEA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_8A7602897846","predicate":"quarterly_operating_income","value":"1,904,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,904,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8A7602897846, https://asof.is/claim/clm_8A7602897846, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_8A7602897846","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78F42A193166","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_7673BF825A9D","predicate":"quarterly_revenue","value":"15,776,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 15,776,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7673BF825A9D, https://asof.is/claim/clm_7673BF825A9D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_7673BF825A9D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A1D46B6132E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_A66CE3EA88E8","predicate":"shares_outstanding","value":"1,767,384,632 shares","valid_from":"2025-10-27","valid_to":"2026-02-10","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,384,632 shares\", as of 2025-10-27 (until 2026-02-10). Claim clm_A66CE3EA88E8, https://asof.is/claim/clm_A66CE3EA88E8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_A66CE3EA88E8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F33386E6A71F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_9AD5C074902A","predicate":"total_assets","value":"133,898,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 133,898,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_9AD5C074902A, https://asof.is/claim/clm_9AD5C074902A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_9AD5C074902A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BAF68C4E73F9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_E6BEEAB8A7CC","predicate":"total_equity","value":"-2,642,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -2,642,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E6BEEAB8A7CC, https://asof.is/claim/clm_E6BEEAB8A7CC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E6BEEAB8A7CC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A970AB08DB3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_4595D4B200E2","predicate":"net_income","value":"4,278,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,278,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4595D4B200E2, https://asof.is/claim/clm_4595D4B200E2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_4595D4B200E2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A3E6A20A337","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},"to":{"id":"clm_2A3E6A20A337","predicate":"net_income","value":"4,226,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,226,000,000 United States dollar\", as of 2025-12-31. Claim clm_2A3E6A20A337, https://asof.is/claim/clm_2A3E6A20A337, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_2A3E6A20A337","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-20"}}},{"predicate":"operating_income","from":{"id":"clm_7198B453007F","predicate":"operating_income","value":"9,137,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 9,137,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_7198B453007F, https://asof.is/claim/clm_7198B453007F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_7198B453007F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D4AF640165D7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},"to":{"id":"clm_D4AF640165D7","predicate":"operating_income","value":"15,075,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 15,075,000,000 United States dollar\", as of 2025-12-31. Claim clm_D4AF640165D7, https://asof.is/claim/clm_D4AF640165D7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_D4AF640165D7","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-20"}}},{"predicate":"revenue","from":{"id":"clm_46C087CADCC6","predicate":"revenue","value":"56,334,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 56,334,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_46C087CADCC6, https://asof.is/claim/clm_46C087CADCC6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_46C087CADCC6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4A7BE8ED0078","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-14"}},"to":{"id":"clm_4A7BE8ED0078","predicate":"revenue","value":"61,160,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 61,160,000,000 United States dollar\", as of 2025-12-31. Claim clm_4A7BE8ED0078, https://asof.is/claim/clm_4A7BE8ED0078, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_4A7BE8ED0078","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-20"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}